1
|
Abstract
Self-adjuvanting vaccines, covalent conjugates between antigens and adjuvants, are chemically well-defined compared with conventional vaccines formulated through mixing antigens with adjuvants. Innate immune receptor ligands effectively induce acquired immunity through the activation of innate immunity, thereby enhancing host immune responses. Thus, innate immune receptor ligands are often used as adjuvants in self-adjuvanting vaccines. In a self-adjuvanting vaccine, the covalent linkage of antigen and adjuvant enables their simultaneous uptake into immune cells where the adjuvant consequently induces antigen-specific immune responses. Importantly, self-adjuvanting vaccines do not require immobilization to carrier proteins or co-administration of additional adjuvants and thus avoid inducing undesired immune responses. Because of these excellent properties, self-adjuvanting vaccines are expected to be candidates for next-generation vaccines. Here, we take an overview of vaccine adjuvants, mainly focusing on those utilized in self-adjuvanting vaccines and then we review recent reports on self-adjuvanting conjugate vaccines.
Collapse
|
2
|
Abboud SA, Cisse EH, Doudeau M, Bénédetti H, Aucagne V. A straightforward methodology to overcome solubility challenges for N-terminal cysteinyl peptide segments used in native chemical ligation. Chem Sci 2021; 12:3194-3201. [PMID: 34164087 PMCID: PMC8179351 DOI: 10.1039/d0sc06001a] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Accepted: 01/10/2021] [Indexed: 02/06/2023] Open
Abstract
One of the main limitations encountered during the chemical synthesis of proteins through native chemical ligation (NCL) is the limited solubility of some of the peptide segments. The most commonly used solution to overcome this problem is to derivatize the segment with a temporary solubilizing tag. Conveniently, the tag can be introduced on the thioester segment in such a way that it is removed concomitantly with the NCL reaction. We herein describe a generalization of this approach to N-terminal cysteinyl segment counterparts, using a straightforward synthetic approach that can be easily automated from commercially available building blocks, and applied it to a well-known problematic target, SUMO-2.
Collapse
Affiliation(s)
- Skander A Abboud
- Centre de Biophysique Moléculaire, CNRS UPR 4301 Rue Charles Sadron 45071 Orléans Cedex 2 France
| | - El Hadji Cisse
- Centre de Biophysique Moléculaire, CNRS UPR 4301 Rue Charles Sadron 45071 Orléans Cedex 2 France
| | - Michel Doudeau
- Centre de Biophysique Moléculaire, CNRS UPR 4301 Rue Charles Sadron 45071 Orléans Cedex 2 France
| | - Hélène Bénédetti
- Centre de Biophysique Moléculaire, CNRS UPR 4301 Rue Charles Sadron 45071 Orléans Cedex 2 France
| | - Vincent Aucagne
- Centre de Biophysique Moléculaire, CNRS UPR 4301 Rue Charles Sadron 45071 Orléans Cedex 2 France
| |
Collapse
|
3
|
Pineda-Castañeda HM, Insuasty-Cepeda DS, Niño-Ramírez VA, Curtidor H, Rivera-Monroy ZJ. Designing Short Peptides: A Sisyphean Task? CURR ORG CHEM 2020. [DOI: 10.2174/1385272824999200910094034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Over the last few years, short peptides have become a powerful tool in basic and
applied research, with different uses like diagnostic, antimicrobial peptides, human health
promoters or bioactive peptides, therapeutic treatments, templates for peptidomimetic design,
and peptide-based vaccines. In this endeavor, different approaches and technologies
have been explored, such as bioinformatics, large-scale peptide synthesis, omics sciences,
structure-activity relationship studies, and a biophysical approach, among others, seeking to
obtain the shortest sequence with the best activity. The advantage of short peptides lies in
their stability, ease of production, safety, and low cost. There are many strategies for designing
short peptides with biomedical and industrial applications (targeting the structure, length,
charge, or polarity) or as a starting point for improving their properties (sequence data base,
de novo sequences, templates, or organic scaffolds). In peptide design, it is necessary to keep in mind factors
such as the application (peptidomimetic, immunogen, antimicrobial, bioactive, or protein-protein interaction
inhibitor), the expected target (membrane cell, nucleus, receptor proteins, or immune system), and particular
characteristics (shorter, conformationally constrained, cycled, charged, flexible, polymerized, or pseudopeptides).
This review summarizes the different synthetic approaches and strategies used to design new peptide analogs,
highlighting the achievements, constraints, and advantages of each.
Collapse
Affiliation(s)
| | | | - Víctor A. Niño-Ramírez
- Chemistry Department, Sciences Faculty, Universidad Nacional de Colombia, Bogota, Colombia
| | | | - Zuly J. Rivera-Monroy
- Chemistry Department, Sciences Faculty, Universidad Nacional de Colombia, Bogota, Colombia
| |
Collapse
|
4
|
Manabe Y, Chang TC, Fukase K. Recent advances in self-adjuvanting glycoconjugate vaccines. DRUG DISCOVERY TODAY. TECHNOLOGIES 2020; 37:61-71. [PMID: 34895656 DOI: 10.1016/j.ddtec.2020.11.006] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/18/2020] [Revised: 07/21/2020] [Accepted: 11/26/2020] [Indexed: 01/02/2023]
Abstract
Compared to traditional vaccines that are formulated into mixtures of an adjuvant and an antigen, a self-adjuvanting vaccine consists of an antigen that is covalently conjugated to a well-defined adjuvant. In self-adjuvanting vaccines, innate immune receptor ligands are usually used as adjuvants. Innate immune receptor ligands effectively trigger acquired immunity through the activation of innate immunity to enhance host immune responses to antigens. When a self-adjuvanting vaccine is used, immune cells simultaneously uptake the antigen and the adjuvant because they are covalently linked. Consequently, the adjuvant can specifically induce immune responses against the conjugated antigen. Importantly, self-adjuvanting vaccines do not require co-administration of additional adjuvants or immobilization to carrier proteins, which enables avoidance of the use of highly toxic adjuvants or the induction of undesired immune responses. Given these excellent properties, self-adjuvanting vaccines are expected to serve as candidates for the next generation of vaccines. Herein, we review vaccine adjuvants, with a focus on the adjuvants used in self-adjuvanting vaccines, and then overview recent advances made with self-adjuvanting conjugate vaccines.
Collapse
Affiliation(s)
- Yoshiyuki Manabe
- Department of Chemistry, Graduate School of Science, Osaka University, Japan; Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Japan.
| | - Tsung-Che Chang
- Department of Chemistry, Graduate School of Science, Osaka University, Japan
| | - Koichi Fukase
- Department of Chemistry, Graduate School of Science, Osaka University, Japan; Core for Medicine and Science Collaborative Research and Education, Project Research Center for Fundamental Sciences, Graduate School of Science, Osaka University, Japan.
| |
Collapse
|
5
|
Marqvorsen MHS, Araman C, van Kasteren SI. Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System. Bioconjug Chem 2019; 30:2715-2726. [PMID: 31580646 PMCID: PMC6873266 DOI: 10.1021/acs.bioconjchem.9b00588] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2019] [Revised: 09/30/2019] [Indexed: 12/16/2022]
Abstract
Glycosylation plays a myriad of roles in the immune system: Certain glycans can interact with specific immune receptors to kickstart a pro-inflammatory response, whereas other glycans can do precisely the opposite and ameliorate the immune response. Specific glycans and glycoforms can themselves become the targets of the adaptive immune system, leading to potent antiglycan responses that can lead to the killing of altered self- or pathogenic species. This hydra-like set of roles glycans play is of particular importance in cancer immunity, where it influences the anticancer immune response, likely playing pivotal roles in tumor survival or clearance. The complexity of carbohydrate biology requires synthetic access to glycoproteins and glycopeptides that harbor homogeneous glycans allowing the probing of these systems with high precision. One particular complicating factor in this is that these synthetic structures are required to be as close to the native structures as possible, as non-native linkages can themselves elicit immune responses. In this Review, we discuss examples and current strategies for the synthesis of natively linked single glycoforms of peptides and proteins that have enabled researchers to gain new insights into glycoimmunology, with a particular focus on the application of these reagents in cancer immunology.
Collapse
Affiliation(s)
- Mikkel H. S. Marqvorsen
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Can Araman
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| | - Sander I. van Kasteren
- Leiden
Institute of Chemistry, Institute for Chemical Immunology Gorlaeus
Laboratories, Leiden University, Einsteinweg 55, 2333 CC, Leiden, The Netherlands
| |
Collapse
|
6
|
McDonald DM, Hanna CC, Ashhurst AS, Corcilius L, Byrne SN, Payne RJ. Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization. ACS Chem Biol 2018; 13:3279-3285. [PMID: 30359529 DOI: 10.1021/acschembio.8b00675] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Access to lipopeptide-based vaccines for immunological studies remains a significant challenge owing to the amphipathic nature of the molecules, which makes them difficult to synthesize and purify to homogeneity. Here, we describe the application of a new peptide ligation technology, the diselenide-selenoester ligation (DSL), to access self-adjuvanting glycolipopeptide vaccines. We show that rapid ligation of glyco- and lipopeptides is possible via DSL in mixed organic solvent-aqueous buffer and, when coupled with deselenization chemistry, affords rapid and efficient access to a vaccine candidate possessing a MUC1 glycopeptide epitope and the lipopeptide adjuvant Pam2Cys. This construct was shown to elicit MUC1-specific antibody and cytotoxic T lymphocyte responses in the absence of any other injected lipids or adjuvants. The inclusion of the helper T cell epitope PADRE both boosted the antibody response and resulted in elevated cytokine production.
Collapse
Affiliation(s)
- David M. McDonald
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Cameron C. Hanna
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Anneliese S. Ashhurst
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Leo Corcilius
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Scott N. Byrne
- Infectious Diseases and Immunology, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales 2006, Australia
| | - Richard J. Payne
- School of Chemistry, The University of Sydney, Sydney, New South Wales 2006, Australia
| |
Collapse
|
7
|
Li Q, Guo Z. Recent Advances in Toll Like Receptor-Targeting Glycoconjugate Vaccines. Molecules 2018; 23:molecules23071583. [PMID: 29966261 PMCID: PMC6100623 DOI: 10.3390/molecules23071583] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 06/25/2018] [Accepted: 06/28/2018] [Indexed: 02/04/2023] Open
Abstract
Many malignant cell surface carbohydrates resulting from abnormal glycosylation patterns of certain diseases can serve as antigens for the development of vaccines against these diseases. However, carbohydrate antigens are usually poorly immunogenic by themselves, thus they need to be covalently coupled with immunologically active carrier molecules to be functional. The most well established and commonly used carriers are proteins. In recent years, the use of toll-like receptor (TLR) ligands to formulate glycoconjugate vaccines has gained significant attention because TLR ligands can serve not only as carrier molecules but also as built-in adjuvants to form fully synthetic and self-adjuvanting conjugate vaccines, which have several advantages over carbohydrate-protein conjugates and formulated mixtures with external adjuvants. This article reviews recent progresses in the development of conjugate vaccines based on TLR ligands. Two major classes of TLR ligands, lipopeptides and lipid A derivatives will be covered with more focus on monophosohoryl lipid A (MPLA) and related analogs, which are TLR4 ligands demonstrated to be able to provoke T cell-dependent, adaptive immune responses. Corresponding conjugate vaccines have shown promising application potentials to multiple diseases including cancer.
Collapse
Affiliation(s)
- Qingjiang Li
- Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, FL 32611, USA.
| | - Zhongwu Guo
- Department of Chemistry, University of Florida, 214 Leigh Hall, Gainesville, FL 32611, USA.
| |
Collapse
|
8
|
Kowalczyk R, Harris PWR, Williams GM, Yang SH, Brimble MA. Peptide Lipidation - A Synthetic Strategy to Afford Peptide Based Therapeutics. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2018; 1030:185-227. [PMID: 29081055 PMCID: PMC7121180 DOI: 10.1007/978-3-319-66095-0_9] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Peptide and protein aberrant lipidation patterns are often involved in many diseases including cancer and neurological disorders. Peptide lipidation is also a promising strategy to improve pharmacokinetic and pharmacodynamic profiles of peptide-based drugs. Self-adjuvanting peptide-based vaccines commonly utilise the powerful TLR2 agonist PamnCys lipid to stimulate adjuvant activity. The chemical synthesis of lipidated peptides can be challenging hence efficient, flexible and straightforward synthetic routes to access homogeneous lipid-tagged peptides are in high demand. A new technique coined Cysteine Lipidation on a Peptide or Amino acid (CLipPA) uses a 'thiol-ene' reaction between a cysteine and a vinyl ester and offers great promise due to its simplicity, functional group compatibility and selectivity. Herein a brief review of various synthetic strategies to access lipidated peptides, focusing on synthetic methods to incorporate a PamnCys motif into peptides, is provided.
Collapse
Affiliation(s)
- Renata Kowalczyk
- School of Chemical Sciences, The University of Auckland, 23 Symonds St, Auckland, New Zealand
| | - Paul W R Harris
- School of Chemical Sciences, The University of Auckland, 23 Symonds St, Auckland, New Zealand.,School of Biological Sciences, The University of Auckland, 3A Symonds St, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, 1010, New Zealand
| | - Geoffrey M Williams
- School of Chemical Sciences, The University of Auckland, 23 Symonds St, Auckland, New Zealand.,School of Biological Sciences, The University of Auckland, 3A Symonds St, Auckland, New Zealand.,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, 1010, New Zealand
| | - Sung-Hyun Yang
- School of Chemical Sciences, The University of Auckland, 23 Symonds St, Auckland, New Zealand.,School of Biological Sciences, The University of Auckland, 3A Symonds St, Auckland, New Zealand
| | - Margaret A Brimble
- School of Chemical Sciences, The University of Auckland, 23 Symonds St, Auckland, New Zealand. .,School of Biological Sciences, The University of Auckland, 3A Symonds St, Auckland, New Zealand. .,Maurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Private Bag 92019, Auckland, 1010, New Zealand.
| |
Collapse
|
9
|
Ignacio BJ, Albin TJ, Esser-Kahn AP, Verdoes M. Toll-like Receptor Agonist Conjugation: A Chemical Perspective. Bioconjug Chem 2018; 29:587-603. [PMID: 29378134 PMCID: PMC10642707 DOI: 10.1021/acs.bioconjchem.7b00808] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Toll-like receptors (TLRs) are vital elements of the mammalian immune system that function by recognizing pathogen-associated molecular patterns (PAMPs), bridging innate and adaptive immunity. They have become a prominent therapeutic target for the treatment of infectious diseases, cancer, and allergies, with many TLR agonists currently in clinical trials or approved as immunostimulants. Numerous studies have shown that conjugation of TLR agonists to other molecules can beneficially influence their potency, toxicity, pharmacokinetics, or function. The functional properties of TLR agonist conjugates, however, are highly dependent on the ligation strategy employed. Here, we review the chemical structural requirements for effective functional TLR agonist conjugation. In addition, we provide similar analysis for those that have yet to be conjugated. Moreover, we discuss applications of covalent TLR agonist conjugation and their implications for clinical use.
Collapse
Affiliation(s)
- Bob J. Ignacio
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| | - Tyler J. Albin
- Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States
| | - Aaron P. Esser-Kahn
- Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States
- Institute for Molecular Engineering, University of Chicago, Chicago, Illinois 60637, United States
| | - Martijn Verdoes
- Department of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
| |
Collapse
|
10
|
McDonald DM, Byrne SN, Payne RJ. Synthetic self-adjuvanting glycopeptide cancer vaccines. Front Chem 2015; 3:60. [PMID: 26557640 PMCID: PMC4615963 DOI: 10.3389/fchem.2015.00060] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 10/07/2015] [Indexed: 12/05/2022] Open
Abstract
Due to changes in glycosyltransferase expression during oncogenesis, the glycoproteins of cancer cells often carry highly truncated carbohydrate chains compared to those on healthy cells. These glycans are known as tumor-associated carbohydrate antigens (TACAs), and are prime targets for use in vaccines for the prevention and treatment of cancer. Herein, we review the state-of-the-art in targeting the immune system toward tumor-associated glycopeptide antigens via synthetic self-adjuvanting vaccines, in which the antigenic and adjuvanting moieties of the vaccines are present in the same molecule. The majority of the self-adjuvanting glycopeptide cancer vaccines reported to date employ antigens from mucin 1, a protein which is highly over-expressed and aberrantly glycosylated in many forms of cancer. The adjuvants used in these vaccines predominantly include lipopeptide- or lipoamino acid-based TLR2 agonists, although studies investigating stimulation of TLR9 and TLR4 are also discussed. Many of these adjuvants are highly lipophilic, and, upon conjugation to antigenic peptides, provide amphiphilic vaccine molecules. The amphiphilic nature of these vaccine constructs can lead to the formation of higher-order structures by vaccines in solution, which are likely to be important for their efficacy in vivo.
Collapse
Affiliation(s)
- David M. McDonald
- School of Chemistry, The University of SydneySydney, NSW, Australia
- Discipline of Infectious Diseases and Immunology, The University of SydneySydney, NSW, Australia
| | - Scott N. Byrne
- Discipline of Infectious Diseases and Immunology, The University of SydneySydney, NSW, Australia
| | - Richard J. Payne
- School of Chemistry, The University of SydneySydney, NSW, Australia
| |
Collapse
|
11
|
Tavernaro I, Hartmann S, Sommer L, Hausmann H, Rohner C, Ruehl M, Hoffmann-Roeder A, Schlecht S. Synthesis of tumor-associated MUC1-glycopeptides and their multivalent presentation by functionalized gold colloids. Org Biomol Chem 2015; 13:81-97. [PMID: 25212389 DOI: 10.1039/c4ob01339e] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The mucin MUC1 is a glycoprotein involved in fundamental biological processes, which can be found over-expressed and with a distinctly altered glycan pattern on epithelial tumor cells; thus it is a promising target structure in the quest for effective carbohydrate-based cancer vaccines and immunotherapeutics. Natural glycopeptide antigens indicate only a low immunogenicity and a T-cell independent immune response; however, this major drawback can be overcome by coupling of glycopeptide antigens multivalently to immunostimulating carrier platforms. In particular, gold nanoparticles are well suited as templates for the multivalent presentation of glycopeptide antigens, due to their remarkably high surface-to-volume ratio in combination with their high biostability. In this work the synthesis of novel MUC1-glycopeptide antigens and their coupling to gold nanoparticles of different sizes are presented. In addition, the development of a new dot-blot immunoassay to test the potential antigen-antibody binding is introduced.
Collapse
Affiliation(s)
- Isabella Tavernaro
- Institute of Inorganic and Analytical Chemistry, Justus-Liebig-University Giessen, Heinrich-Buff-Ring 58, 35392 Giessen, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Thompson P, Lakshminarayanan V, Supekar NT, Bradley JM, Cohen PA, Wolfert MA, Gendler SJ, Boons GJ. Linear synthesis and immunological properties of a fully synthetic vaccine candidate containing a sialylated MUC1 glycopeptide. Chem Commun (Camb) 2015; 51:10214-7. [PMID: 26022217 DOI: 10.1039/c5cc02199e] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
A strategy for the linear synthesis of a sialylated glycolipopeptide cancer vaccine candidate has been developed using a strategically designed sialyl-Tn building block and microwave-assisted solid-phase peptide synthesis. The glycolipopeptide elicited potent humoral and cellular immune responses. T-cells primed by such a vaccine candidate could be restimulated by tumor-associated MUC1.
Collapse
Affiliation(s)
- Pamela Thompson
- Complex Carbohydrate Research Center, The University of Georgia, 315 Riverbend Road, Athens, GA 30602, USA.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Islam M, Shaikh AY, Hotha S. Transition Metals for the Synthesis of Glycopolymers and Glycopolypeptides. Isr J Chem 2015. [DOI: 10.1002/ijch.201400202] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
14
|
Ramakers BEI, van Hest JCM, Löwik DWPM. Molecular tools for the construction of peptide-based materials. Chem Soc Rev 2014; 43:2743-56. [PMID: 24448606 DOI: 10.1039/c3cs60362h] [Citation(s) in RCA: 83] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Proteins and peptides are fundamental components of living systems where they play crucial roles at both functional and structural level. The versatile biological properties of these molecules make them interesting building blocks for the construction of bio-active and biocompatible materials. A variety of molecular tools can be used to fashion the peptides necessary for the assembly of these materials. In this tutorial review we shall describe five of the main techniques, namely solid phase peptide synthesis, native chemical ligation, Staudinger ligation, NCA polymerisation, and genetic engineering, that have been used to great effect for the construction of a host of peptide-based materials.
Collapse
Affiliation(s)
- B E I Ramakers
- Radboud University Nijmegen, Institute for Molecules and Materials, Bio-Organic Chemistry, Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.
| | | | | |
Collapse
|
15
|
Verzele D, Madder A. Patchwork protein chemistry: a practitioner's treatise on the advances in synthetic peptide stitchery. Chembiochem 2014; 14:1032-48. [PMID: 23775826 DOI: 10.1002/cbic.201200775] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2012] [Indexed: 12/22/2022]
Abstract
With the study of peptides and proteins at the heart of many scientific endeavors, the omics era heralded a multitude of opportunities for chemists and biologists alike. Across the interface with life sciences, peptide chemistry plays an indispensable role, and progress made over the past decades now allows proteins to be treated as molecular patchworks stitched together through synthetic tailoring. The continuous elaboration of sophisticated strategies notwithstanding, Merrifield's solid-phase methodology remains a cornerstone of chemical protein design. Although the non-practitioner might misjudge peptide synthesis as trivial, routine, or dull given its long history, we comment here on its many advances, obstacles, and prospects from a practitioner's point of view. While sharing our perspectives through thematic highlights across the literature, this treatise provides an interpretive overview as a guide to novices, and a recap for specialists.
Collapse
Affiliation(s)
- Dieter Verzele
- Organic and Biomimetic Chemistry Research Group, Department of Organic Chemistry, Faculty of Sciences, Ghent University, Krijgslaan 281 (S4), 9000 Ghent, Belgium.
| | | |
Collapse
|
16
|
Gaidzik N, Westerlind U, Kunz H. The development of synthetic antitumour vaccines from mucin glycopeptide antigens. Chem Soc Rev 2013; 42:4421-42. [PMID: 23440054 DOI: 10.1039/c3cs35470a] [Citation(s) in RCA: 344] [Impact Index Per Article: 31.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Based on important cell-biological and biochemical results concerning the structural difference between membrane glycoproteins of normal epithelial cells and epithelial tumour cells, tumour-associated glycopeptide antigens have been chemically synthesised and structurally confirmed. Glycopeptide structures of the tandem repeat sequence of mucin MUC1 of epithelial tumour cells constitute the most promising tumour-associated antigens. In order to generate a sufficient immunogenicity of these endogenous structures, usually tolerated by the immune system, these synthetic glycopeptide antigens were conjugated to immune stimulating components: in fully synthetic two-component vaccines either with T-cell peptide epitopes or with Toll-like receptor2 lipopeptide ligands or in three-component vaccines with both these stimulants. Alternatively, the synthetic glycopeptide antigens were coupled to immune stimulating carrier proteins. In particular, MUC1 glycopeptide conjugates with Tetanus toxoid proved to be efficient vaccines inducing very strong immune responses in mice. The antibodies elicited with the fully synthetic vaccines showed selective recognition of the tumour-associated glycopeptides as was shown by neutralisation and micro-array binding experiments. After booster immunisations, most of the immune responses showed the installation of an immunological memory. Immunisation with fully synthetic three-component vaccines induced immune reactions with therapeutic effects in terms of reduction of the tumour burden in mice or in killing of tumour cells in culture, while MUC1 glycopeptide-Tetanus toxoid vaccines elicited antibodies in mice which recognised tumour cells in human tumour tissues. The results achieved so far are considered to be promising for the development of an active immunisation against tumours.
Collapse
Affiliation(s)
- Nikola Gaidzik
- Johannes Gutenberg-Universität Mainz, Institut für Organische Chemiem, Duesbergweg 10-14, D-55128 Mainz, Germany
| | | | | |
Collapse
|
17
|
Hemantha HP, Narendra N, Sureshbabu VV. Total chemical synthesis of polypeptides and proteins: chemistry of ligation techniques and beyond. Tetrahedron 2012. [DOI: 10.1016/j.tet.2012.08.059] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
18
|
Abdel-Aal ABM, El-Naggar D, Zaman M, Batzloff M, Toth I. Design of fully synthetic, self-adjuvanting vaccine incorporating the tumor-associated carbohydrate Tn antigen and lipoamino acid-based Toll-like receptor 2 ligand. J Med Chem 2012; 55:6968-74. [PMID: 22800462 DOI: 10.1021/jm300822g] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Overexpression of certain tumor-associated carbohydrate antigens (TACA) caused by malignant transformation offers promising targets to develop novel antitumor vaccines, provided the ability to break their inherent low immunogenicity and overcome the tolerance of the immune system. We designed, synthesized, and immunologically evaluated a number of fully synthetic new chimeric constructs incorporating a cluster of the most common TACA (known as Tn antigen) covalently attached to T-cell peptide epitopes derived from polio virus and ovalbumin and included a synthetic built-in adjuvant consisting of two 16-carbon lipoamino acids. Vaccine candidates were able to induce significantly strong antibody responses in mice without the need for any additional adjuvant, carrier protein, or special pharmaceutical preparation (e.g., liposomes). Vaccine constructs were assembled either in a linear or in a branched architecture, which demonstrated the intervening effects of the incorporation and arrangement of T-cell epitopes on antibody recognition.
Collapse
Affiliation(s)
- Abu-Baker M Abdel-Aal
- School of Chemistry and Molecular Biosciences (SCMB), The University of Queensland , QLD 4072, Queensland, Australia
| | | | | | | | | |
Collapse
|
19
|
Carbohydrate-based cancer vaccines: target cancer with sugar bullets. Glycoconj J 2012; 29:259-71. [DOI: 10.1007/s10719-012-9399-9] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2012] [Revised: 05/12/2012] [Accepted: 05/21/2012] [Indexed: 12/31/2022]
|
20
|
Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies. Future Med Chem 2012; 4:545-84. [DOI: 10.4155/fmc.11.193] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Cancer cells can often be distinguished from healthy cells by the expression of unique carbohydrate sequences decorating the cell surface as a result of aberrant glycosyltransferase activity occurring within the cell; these unusual carbohydrates can be used as valuable immunological targets in modern vaccine designs to raise carbohydrate-specific antibodies. Many tumor antigens (e.g., GM2, Ley, globo H, sialyl Tn and TF) have been identified to date in a variety of cancers. Unfortunately, carbohydrates alone evoke poor immunogenicity, owing to their lack of ability in inducing T-cell-dependent immune responses. In order to enhance their immunogenicity and promote long-lasting immune responses, carbohydrates are often chemically modified to link to an immunogenic protein or peptide fragment for eliciting T-cell-dependent responses. This review will present a summary of efforts and advancements made to date on creating carbohydrate-based anticancer vaccines, and will include novel approaches to overcoming the poor immunogenicity of carbohydrate-based vaccines.
Collapse
|
21
|
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine. Proc Natl Acad Sci U S A 2011; 109:261-6. [PMID: 22171012 DOI: 10.1073/pnas.1115166109] [Citation(s) in RCA: 437] [Impact Index Per Article: 33.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The mucin MUC1 is typically aberrantly glycosylated by epithelial cancer cells manifested by truncated O-linked saccharides. The resultant glycopeptide epitopes can bind cell surface major histocompatibility complex (MHC) molecules and are susceptible to recognition by cytotoxic T lymphocytes (CTLs), whereas aberrantly glycosylated MUC1 protein on the tumor cell surface can be bound by antibodies to mediate antibody-dependent cell-mediated cytotoxicity (ADCC). Efforts to elicit CTLs and IgG antibodies against cancer-expressed MUC1 have not been successful when nonglycosylated MUC1 sequences were used for vaccination, probably due to conformational dissimilarities. Immunizations with densely glycosylated MUC1 peptides have also been ineffective due to impaired susceptibility to antigen processing. Given the challenges to immuno-target tumor-associated MUC1, we have identified the minimum requirements to consistently induce CTLs and ADCC-mediating antibodies specific for the tumor form of MUC1 resulting in a therapeutic response in a mouse model of mammary cancer. The vaccine is composed of the immunoadjuvant Pam(3)CysSK(4), a peptide T(helper) epitope and an aberrantly glycosylated MUC1 peptide. Covalent linkage of the three components was essential for maximum efficacy. The vaccine produced CTLs, which recognized both glycosylated and nonglycosylated peptides, whereas a similar nonglycosylated vaccine gave CTLs which recognized only nonglycosylated peptide. Antibodies elicited by the glycosylated tripartite vaccine were significantly more lytic compared with the unglycosylated control. As a result, immunization with the glycosylated tripartite vaccine was superior in tumor prevention. Besides its own aptness as a clinical target, these studies of MUC1 are likely predictive of a covalent linking strategy applicable to many additional tumor-associated antigens.
Collapse
|
22
|
Hsu CH, Hung SC, Wu CY, Wong CH. Toward automated oligosaccharide synthesis. Angew Chem Int Ed Engl 2011; 50:11872-923. [PMID: 22127846 DOI: 10.1002/anie.201100125] [Citation(s) in RCA: 205] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2011] [Indexed: 12/16/2022]
Abstract
Carbohydrates have been shown to play important roles in biological processes. The pace of development in carbohydrate research is, however, relatively slow due to the problems associated with the complexity of carbohydrate structures and the lack of general synthetic methods and tools available for the study of this class of biomolecules. Recent advances in synthesis have demonstrated that many of these problems can be circumvented. In this Review, we describe the methods developed to tackle the problems of carbohydrate-mediated biological processes, with particular focus on the issue related to the development of the automated synthesis of oligosaccharides. Further applications of carbohydrate microarrays and vaccines to human diseases are also highlighted.
Collapse
Affiliation(s)
- Che-Hsiung Hsu
- The Genomics Research Center, Academia Sinica, Taipei, Taiwan
| | | | | | | |
Collapse
|
23
|
Hsu CH, Hung SC, Wu CY, Wong CH. Auf dem Weg zur automatisierten Oligosaccharid- Synthese. Angew Chem Int Ed Engl 2011. [DOI: 10.1002/ange.201100125] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
24
|
Morelli L, Poletti L, Lay L. Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation. European J Org Chem 2011. [DOI: 10.1002/ejoc.201100296] [Citation(s) in RCA: 117] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Laura Morelli
- Dipartimento di Chimica Organica e Industriale, CISI and ISTM‐CNR, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Laura Poletti
- Dipartimento di Chimica Organica e Industriale, CISI and ISTM‐CNR, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| | - Luigi Lay
- Dipartimento di Chimica Organica e Industriale, CISI and ISTM‐CNR, Università degli Studi di Milano, Via Venezian 21, 20133 Milano, Italy
| |
Collapse
|
25
|
Cai H, Huang ZH, Shi L, Zhao YF, Kunz H, Li YM. Towards a fully synthetic MUC1-based anticancer vaccine: efficient conjugation of glycopeptides with mono-, di-, and tetravalent lipopeptides using click chemistry. Chemistry 2011; 17:6396-406. [PMID: 21538615 DOI: 10.1002/chem.201100217] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2011] [Indexed: 11/08/2022]
Abstract
The membrane-bound tumor-associated glycoprotein MUC1 is aberrantly glycosylated in cancer cells compared with normal cells, and is therefore considered an attractive target for cancer immunotherapy. However, tumor-associated glycopeptides from MUC1 do not elicit a sufficiently robust immune response. Therefore, antitumor vaccines were developed, which consist of MUC1 glycopeptides as the B epitopes and immune-stimulating toll-like receptor 2 (TLR 2) lipopeptide ligands. These fully synthetic vaccine candidates were prepared by solid-phase synthesis of the MUC1 glycopeptides. The Pam(3) Cys lipopeptide, also synthesized on solid-phase, was C-terminally coupled to oligovalent lysine cores, which N-terminally incorporate O-propargyl oligoethylene glycol acyl side chains. The MUC1 glycopeptides and lipopeptide lysine constructs were then conjugated by click chemistry to give oligovalent synthetic vaccines. Oligovalent glycopeptide-lipopeptide conjugates are considered more immunogenic than their monovalent analogues.
Collapse
Affiliation(s)
- Hui Cai
- Department of Chemistry, Tsinghua University, Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology (Ministry of Education), Tsinghua University, Beijing 100084, PR China
| | | | | | | | | | | |
Collapse
|
26
|
Westerlind U, Kunz H. Synthetic vaccines based on N- and O-glycopeptides–molecular tools for immunotherapy and diagnostics. CARBOHYDRATE CHEMISTRY 2010. [DOI: 10.1039/9781849730891-00001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
This chapter summarizes available methods for the preparation of synthetic vaccines based on glycopeptides and recent advances in this field. It further includes results of their immunological evaluation. Syntheses of glycopeptides of defined chemical structure and conjugation of these compounds to a carrier protein or an immunostimulant are of interest for the development of new immunotherapeutics and/or antibody-based diagnostics. Since a number of years, the aberrant glycosylation of the tumorassociated mucin MUC1 forming tumor specific epitopes on the epithelial cell surface has been considered an attractive research target for the preparation of such vaccines. Examples of synthetic vaccines directed against the O-glycosylated MUC1 tandem repeats will here be given including synthetic MUC1 glycopeptides conjugated to a T-cell epitope peptide, to a carrier protein, to a lipid immunostimulant or the multimeric presentation of glycopeptides on dendrimers. Other attractive targets for immunotherapy are the viral envelope proteins HIV gp120 and HIV gp41 , which are highly glycosylated with high-mannose and complex type N-glycans. Examples will be given, which illustrate syntheses of high-mannose HIV gp120 or gp41 glycopeptides with the natural peptide backbone or with a non-natural cyclic backbone to mimic the high-mannose cluster domain of HIV gp120. In addition the synthesis and immunological evaluation of a vaccine will be described, which contains the high-mannose cluster mimotope glycopeptide conjugated to an outer membrane protein complex (OMPC) as the carrier.
Collapse
Affiliation(s)
| | - Horst Kunz
- Institut für Organische Chemie, Universität Mainz Mainz Germany
| |
Collapse
|
27
|
Zheng JS, Cui HK, Fang GM, Xi WX, Liu L. Chemical protein synthesis by kinetically controlled ligation of peptide O-esters. Chembiochem 2010; 11:511-5. [PMID: 20157912 DOI: 10.1002/cbic.200900789] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Ji-Shen Zheng
- Department of Chemistry, Key Laboratory of Bioorganic Phosphorus Chemistry and Chemical Biology, Tsinghua University, Beijing 100084, China
| | | | | | | | | |
Collapse
|
28
|
Payne RJ, Wong CH. Advances in chemical ligation strategies for the synthesis of glycopeptides and glycoproteins. Chem Commun (Camb) 2010; 46:21-43. [DOI: 10.1039/b913845e] [Citation(s) in RCA: 191] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
29
|
Buskas T, Thompson P, Boons GJ. Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chem Commun (Camb) 2009:5335-49. [PMID: 19724783 PMCID: PMC2787243 DOI: 10.1039/b908664c] [Citation(s) in RCA: 158] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Aberrant glycosylation of glycoproteins and glycolipids of cancer cells, which correlates with poor survival rates, is being exploited for the development of immunotherapies for cancer. In particular, advances in the knowledge of cooperation between the innate and adaptive system combined with the implementation of efficient synthetic methods for assembly of oligosaccharides and glycopeptides is providing avenues for the rationale design of vaccine candidates. In this respect, fully synthetic vaccine candidates show great promise because they incorporate only those elements requires for relevant immune responses, and hence do not suffer from immune suppression observed with classical carbohydrate-protein conjugate vaccines. Such vaccines are chemically well-defined and it is to be expected that they can be produced in a reproducible fashion. In this feature article, recent advances in the development of fully synthetic sub-unit carbohydrate-based cancer vaccines will be discussed.
Collapse
Affiliation(s)
- Therese Buskas
- Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road, Athens, GA 30602, USA
| | | | | |
Collapse
|
30
|
Ingale S, Wolfert MA, Buskas T, Boons GJ. Increasing the antigenicity of synthetic tumor-associated carbohydrate antigens by targeting Toll-like receptors. Chembiochem 2009; 10:455-63. [PMID: 19145607 DOI: 10.1002/cbic.200800596] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
SYNTHETIC CANCER VACCINES: A number of fully synthetic vaccine candidates have been designed, chemically synthesized, and immunologically evaluated to establish a strategy to overcome the poor immunogenicity of tumor-associated carbohydrates and glycopeptides and to determine the importance of Toll-like receptor (TLR) engagement for antigenic responses against these compounds.Epithelial cancer cells often overexpress mucins that are aberrantly glycosylated. Although it has been realized that these compounds offer exciting opportunities for the development of immunotherapy for cancer, their use is hampered by the low antigenicity of classical immunogens composed of a glycopeptide derived from a mucin conjugated to a foreign carrier protein. We have designed, chemically synthesized, and immunologically evaluated a number of fully synthetic vaccine candidates to establish a strategy to overcome the poor immunogenicity of tumor-associated carbohydrates and glycopeptides. The compounds were also designed to allow study of the importance of Toll-like receptor (TLR) engagement for these antigenic responses in detail. We have found that covalent attachment of a TLR2 agonist, a promiscuous peptide T-helper epitope, and a tumor-associated glycopeptide gives a compound (1) that elicits in mice exceptionally high titers of IgG antibodies that recognize MCF7 cancer cells expressing the tumor-associated carbohydrate. Immunizations with glycolipopeptide 2, which contains lipidated amino acids instead of a TLR2 ligand, gave significantly lower titers of IgG antibodies; this demonstrates that TLR engagement is critical for optimum antigenic responses. Although mixtures of compound 2 with Pam(3)CysSK(4) (3) or monophosphoryl lipid A (4) elicited titers of IgG antibodies similar to those seen with 1, the resulting antisera had impaired ability to recognize cancer cells. It was also found that covalent linkage of the helper T-epitope to the B-epitope is essential, probably because internalization of the helper T-epitope by B-cells requires assistance of the B-epitope. The results presented here show that synthetic vaccine development is amenable to structure-activity relationship studies for successful optimization of carbohydrate-based cancer vaccines.
Collapse
Affiliation(s)
- Sampat Ingale
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA 30602, USA
| | | | | | | |
Collapse
|
31
|
Zhong W, Skwarczynski M, Simerska P, Good MF, Toth I. Development of highly pure α-helical lipoglycopeptides as self-adjuvanting vaccines. Tetrahedron 2009. [DOI: 10.1016/j.tet.2009.02.060] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
32
|
Affiliation(s)
- David P Gamblin
- Department of Chemistry, University of Oxford, Chemistry Research Laboratory, Mansfield Road, Oxford OX1 3TA, United Kingdom
| | | | | |
Collapse
|
33
|
Zhong W, Skwarczynski M, Toth I. Lipid Core Peptide System for Gene, Drug, and Vaccine Delivery. Aust J Chem 2009. [DOI: 10.1071/ch09149] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
A vast number of biologically active compounds await efficient delivery to become therapeutic agents. Lipidation has been demonstrated to be a convenient and useful approach to improve the stability and transport across biological membranes of potential drug molecules. The lipid core peptide (LCP) system has emerged as a promising lipidation tool because of its versatile features. This review discusses the progress in the development of the LCP system to improve cell permeability of nucleotides, physicochemical properties of potential drugs, and vaccine immunogenicity. Emphasis was put on the application of the LCP system to deliver antigens for the prevention of group A streptococcus infection, novel techniques of conjugation of target molecules to the LCP, and new alterations of the LCP system itself.
Collapse
|
34
|
Westerlind U, Hobel A, Gaidzik N, Schmitt E, Kunz H. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. Angew Chem Int Ed Engl 2008; 47:7551-6. [PMID: 18704911 DOI: 10.1002/anie.200802102] [Citation(s) in RCA: 92] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Ulrika Westerlind
- Institut für Organische Chemie, Johannes Gutenberg-Universität Mainz, Duesbergweg 10-14, 55128 Mainz, Germany
| | | | | | | | | |
Collapse
|
35
|
Westerlind U, Hobel A, Gaidzik N, Schmitt E, Kunz H. Synthetische Vakzine aus tumorassoziierten MUC1-Glycopeptidantigenen und einem T-Zellepitop für die Induzierung einer hochspezifischen humoralen Immunantwort. Angew Chem Int Ed Engl 2008. [DOI: 10.1002/ange.200802102] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
36
|
Ozawa C, Katayama H, Hojo H, Nakahara Y, Nakahara Y. Efficient Sequential Segment Coupling Using N-Alkylcysteine-Assisted Thioesterification for Glycopeptide Dendrimer Synthesis. Org Lett 2008; 10:3531-3. [DOI: 10.1021/ol801340m] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Chinatsu Ozawa
- Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University, Kanagawa 259-1292, Japan
| | - Hidekazu Katayama
- Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University, Kanagawa 259-1292, Japan
| | - Hironobu Hojo
- Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University, Kanagawa 259-1292, Japan
| | - Yuko Nakahara
- Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University, Kanagawa 259-1292, Japan
| | - Yoshiaki Nakahara
- Department of Applied Biochemistry, Institute of Glycotechnology, Tokai University, Kanagawa 259-1292, Japan
| |
Collapse
|
37
|
Fujita Y, Moyle PM, Hieu S, Simerska P, Toth I. Investigation toward multi-epitope vaccine candidates using native chemical ligation. Biopolymers 2008; 90:624-32. [DOI: 10.1002/bip.21002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
38
|
Ingale S, Wolfert MA, Gaekwad J, Buskas T, Boons GJ. Robust immune responses elicited by a fully synthetic three-component vaccine. Nat Chem Biol 2007; 3:663-7. [PMID: 17767155 PMCID: PMC2836923 DOI: 10.1038/nchembio.2007.25] [Citation(s) in RCA: 268] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2007] [Accepted: 07/13/2007] [Indexed: 02/03/2023]
Abstract
The overexpression of saccharides such as Globo-H, Lewis(Y) and Tn antigen is a common feature of oncogenic transformed cells. Endeavors to exploit this aberrant glycosylation for cancer vaccine development have been complicated by difficulties in eliciting high titers of IgG antibodies against classical conjugates of tumor-associated carbohydrates to carrier proteins. We have designed, chemically synthesized and immunologically evaluated a number of fully synthetic vaccine candidates to establish strategies to overcome the poor immunogenicity of tumor-associated carbohydrates and glycopeptides. We have found that a three-component vaccine composed of a TLR2 agonist, a promiscuous peptide T-helper epitope and a tumor-associated glycopeptide can elicit in mice exceptionally high titers of IgG antibodies that can recognize cancer cells expressing the tumor-associated carbohydrate. The superior properties of the vaccine candidate are attributed to the local production of cytokines, upregulation of co-stimulatory proteins, enhanced uptake by macrophages and dendritic cells and avoidance of epitope suppression.
Collapse
|
39
|
Abstract
Sugar-assisted ligation (SAL) presents an attractive strategy for the synthesis of glycopeptides, including the synthesis of cysteine-free beta-O-linked and N-linked glycopeptides. Here we extended the utility of SAL for the synthesis of alpha-O-linked glycopeptides and glycoproteins. In order to explore SAL in the context of glycoprotein synthesis, we developed a new chemical synthetic route for the alpha-O-linked glycoprotein diptericin epsilon. In the first stage of our synthesis, diptericin segment Cys(Acm)37-Gly(52) and segment Val(53)-Phe(82) were assembled by SAL through a Gly-Val ligation junction. Subsequently, after Acm deprotection, diptericin segment Cys(37)-Phe(82) was ligated to segment Asp(1)-Asn(36) by means of native chemical ligation (NCL) to give the full sequence of diptericin epsilon. In the final synthetic step, hydrogenolysis was applied to remove the thiol handle from the sugar moiety with the concomitant conversion of mutated Cys(37) into the native alanine residue. In addition, we extended the applicability of SAL to the synthesis of glycopeptides containing cysteine residues by carrying out selective desulfurization of the sulfhydryl-modified sugar moiety in the presence of acetamidomethyl (Acm) protected cysteine residues. The results presented here demonstrated for the first time that SAL could be a general and useful tool in the chemical synthesis of glycoproteins.
Collapse
Affiliation(s)
- Yu-Ying Yang
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Simon Ficht
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | - Ashraf Brik
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
- E-mail: ,
| | - Chi-Huey Wong
- Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
- Genomic Research Center, Academia Sinica, 128 Sec. 2, Academia Road, Nankang, Taipei 115, Taiwan
- E-mail: ,
| |
Collapse
|